The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Related Articles
Liso-cel Demonstrates Significant Responses in Relapsed/Refractory MZL
In the phase 2 TRANSCEND FL trial, lisocabtagene maraleucel met its primary end point of overall response rate in patients with marginal zone lymphoma.
MajesTEC-5 Latest data: Teclistamab-DR ± bortezomib for TE-NDMM
MajesTEC-5 is a phase II trial evaluating teclistamab in combination with DR, with or without bortezomib, for NDMM. During ASH 2024, Marc Raab presented initial…
Radiation-induced cardiac disease: Modern techniques to reduce cardiac toxicity
Continuous advancements in cancer management have resulted in increased long-term survival rates amongst cancer survivors and in turn have exposed the full extent of radiotherapy-associated…
Elacestrant Shows Greater Benefit in Endocrine-Sensitive Breast Cancer
Paolo Tarantino, MD, PhD, discusses the approval of the oral therapy elacestrant for patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with ESR1…
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial
Sacituzumab govitecan (SG), a Trop-2-directed antibody–drug conjugate, demonstrated efficacy and manageable toxicity in the phase II TROPHY-U-01 study in pretreated advanced urothelial carcinoma (aUC). We…
Pertuzumab Retreatment in HER2-Positive Locally Advanced/Metastatic Breast Cancer
As reported in the Journal of Clinical Oncology by Yamamoto et al, the final overall survival analysis of the Japanese phase III PRECIOUS study showed…
Trump administration caps indirect costs at 15%, inviting injunctions, congressional scrutiny The move could gut academic cancer research – The Cancer Letter
Late on Friday, Feb. 7, the Trump administration announced that indirect costs paid on grants to U.S. medical research institutions would—starting immediately—henceforth be capped at…
ASTCT and CIBMTR 2025
Fred Hutch scientists are presenting new research findings at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR on February 12-15, 2025. The ASTCT…
Olaparib in treatment‐refractory isocitrate dehydrogenase 1 (IDH1)– and IDH2‐mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial
Olaparib did not reveal radiographic response for patients with isocitrate dehydrogenase 1 (IDH1)– and IDH2-mutant cholangiocarcinoma. However, prolonged disease control was seen in a subset…
Tandem Meetings Home
The Tandem Meetings are a premier event in the evolving hematopoietic cell transplantation (HCT) and cellular therapy field. Through the scientific program, attendees gain access…
